[go: up one dir, main page]

EP2668157A1 - Antagonistes du récepteur 2 activé par des protéases (par2) - Google Patents

Antagonistes du récepteur 2 activé par des protéases (par2)

Info

Publication number
EP2668157A1
EP2668157A1 EP12701772.1A EP12701772A EP2668157A1 EP 2668157 A1 EP2668157 A1 EP 2668157A1 EP 12701772 A EP12701772 A EP 12701772A EP 2668157 A1 EP2668157 A1 EP 2668157A1
Authority
EP
European Patent Office
Prior art keywords
methyl
carboxamide
phenyl
piperidine
aminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12701772.1A
Other languages
German (de)
English (en)
Inventor
Joe William BOYD
Paul Meo
Michael Higginbottom
Iain Simpson
David Mark MOUNTFORD
Edward Daniel Savory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Cambridge Ltd
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of EP2668157A1 publication Critical patent/EP2668157A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS
  • This invention relates to compounds that are PAR2 receptor antagonists, to compositions containing them, to processes for their preparation, and to their use in medicine, in particular for the treatment of conditions which respond to antagonism of the PAR2 receptor, such as inflammation, intestinal inflammation, inflammatory skin diseases including psoriasis and itch, fibrosis, arthritis, pain, cancer and pancreatitis.
  • Protease activated receptors are a family of seven transmembrane domain G-protein-coupled receptors that are activated by cleavage of their extracellular N-terminal domain by proteolytic enzymes. The newly exposed N- terminal sequence acts as a tethered ligand that binds to the extracellular face of the receptor and activates it.
  • PARs Four PARs have been described that are selectively cleaved by different enzymes; PARI , PAR3 and PAR4 are cleaved by thrombin, PAR2 and PAR4 predominantly by trypsin and tryptase and PAR4 also cleaved by cathepsin G.
  • the Gl tract and pancreas are particularly exposed to a large array of proteases which can activate PAR2 receptors. Trypsin is released into the lumen of the pancreatic duct and the upper Gl tract, for physiological digestive purposes. Other proteases abundant in the Gl tract include those derived from enteric bacteria and those generated during disease processes. On mucosal surfaces, a balance between proteolytic activity and the presence of protease inhibitors such as pancreatic secretory trypsin inhibitor (PSTI) is constantly present.
  • PSTI pancreatic secretory trypsin inhibitor
  • PAR2 receptors are expressed throughout the Gl tract specifically on mast cells, smooth muscle cells, myenteric neurons and endothelial cells, and on both the apical and basolateral sides of enterocytes (Kong et al., 1997). Since trypsin present in the Gl lumen could activate PAR2 on apical surfaces, this receptor may provide a means by which the epithelium "senses" luminal processes. In the gut, motility and secretion are regulated by neurons of the submucosal and myenteric plexi of the gastrointestinal tract. These neurones express PARI , PAR2 and PAR4.
  • PAR2 is expressed by secretomotor neurons in the submucosal plexus of the small intestine, where brief activation of PAR2 by agonists such as SLIGRL-NH 2 or trypsin results in a prolonged depolarisation that is often accompanied by increased excitability. Tryptase also induces a transient depolarization and a sustained increase in neuronal excitability (Linden et al., 2001 ). These observations indicate that PAR2 excites a proportion of myenteric neurons, which may contribute to dysmotility during intestinal inflammation.
  • PAR2 activation is important in the establishment, maintenance, and progression of intestinal inflammation and of fibrosis.
  • Psoriasis is a common skin condition which typically develops as patches
  • a PAR2 antagonist will be effective in the treatment of inflammatory skin diseases including psoriasis and itch.
  • topical or systemic administration of a PAR2 antagonist would reduce the itch caused by local inflammation in psoriasis, and therefore would constitute a targeted treatment for this unchallenged symptom of psoriasis.
  • a PAR2 antagonist will be effective in the treatment of arthritis due to inflammation in or around the joint.
  • the transmission of pain and/or unpleasant sensation is also enhanced by activation of PAR2 receptors as application of activating peptide excites C fibres and sensitises them to heat (Ding-Pfennigdorf et al., 2004).
  • PAR-2 has been implicated in cellular proliferation, invasion and metastasis. There is increasing evidence that PAR2 is an important mediator of tumour progression, with trypsin levels being elevated in gastric, colon, ovarian and lung tumours (Ducroc et al., 2002). In addition PAR-2 is expressed in cancers of the lungs, liver, prostate, thyroid, breast, gastrium, colon, pancreas, gallbladder, melanoma and glioblastoma (see Jahan et al., 2007 and references therein).
  • Tissue factor is a primary component of the clotting cascade which with
  • Factor Vila or Factor Xa can initiate clotting. Cancer patients are frequently in a pro-thrombotic state, apparently partly due to the release of TF containing microparticles (small membranous fragments perhaps released on apoptosis). TF is expressed at high levels in vessel wall fibroblasts but may also be expressed on endothelial and smooth muscle cells (Kasthuri et al., 2009). TF is also heavily implicated in cancer, its expression generally increasing with cancer stage (Kakkar et al., 1995; Kasthuri et al., 2009) and appears to be involved in metastasis (Belting et al., 2005). Indeed TF may play a role in forming the fibrinous clot around metastatic cells which serves to protect them from NK cells and to maintain them in the vasculature (Palumbo et al., 2005, 2007).
  • TF/Factor Vila/Factor Xa complexes stimulate breast carcinoma cell migration and invasion through activation of PAR2 (Hjortoe et al., 2004; Morris et al., 2006).
  • activated PAR2 stimulates EGFR activity and thus cellular proliferation (Caruso et al., 2006); Darmoul et al., 2004).
  • ovarian cancer increase in PAR-2 was seen with progression of the cancer irrespective of the histopathological classification of the tumour type, and high cancer cell PAR-2 expression was associated with a significantly worse prognosis (Jahan et al., 2007).
  • Pancreatitis is an inflammatory condition understood to be the result of undesirable trypsin activity within the pancreas.
  • the biological effects of trypsin in the pancreas have been shown to act through PAR2, which is strongly expressed on the luminal surface of acinar and ductal cells (Ceppa et al., 201 1 ; Laukkarinen et al., 2008).
  • Antagonism of the effects of trypsin at PAR2, within the pancreas, is expected to be an effective treatment for pancreatitis.'
  • PAR2 receptor activation has been shown to be important in inflammatory disorders. Based on in vivo studies in models of inflammatory disorders (Kelso et al, JPET, 2006, 316, 1017-1024, Sevigny, PNAS, 201 1 , 108, 20, 8491 -8496 and Cenac et al, JDR, 2010, 89, 10, 1 123-1 128) it is expected that antagonism of the PAR2 receptor will be effective in the treatment of inflammatory disorders.
  • the PAR2 receptor is regarded as a target for intervention in the treatment of the conditions referred to above.
  • This invention makes available a class of compounds which are antagonists of the PAR2 receptor, and their use in indications which respond to the antagonism of the PAR2 receptor such as those mentioned above.
  • Y is -N(R 1A )- or -C(R 1 B )(R 2 )-;
  • R 1A is -X-R 5 and R 1 B is -Q-R 5 ;
  • X is independently selected from a direct bond, -C(O)-, -(CHR 6 ) P -, -N(R 6 )- or, in either orientation, -(CH 2 CHR 6 )-;
  • Q is independently selected from a direct bond, -0-, S, -N(R 6 )-, -C(O)-, C(H)(OH)-, -(CHR 6 ) P - or, in either orientation, -(CH 2 CHR 6 )-;
  • p 1 or 2;
  • R 5 is a monocyclic aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 or 6 ring atoms, optionally fused to a second aromatic or non-aromatic monocyclic carbocyclic or heterocyclic ring to form a 5-5, 5-6, 6-5, or 6-6 bicyclic ring system, which monocyclic ring or bicyclic ring system is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, CF 3 , Ci- 4 -alkyl, Ci_ 4 -alkoxy and -NR 7A R 7B , wherein
  • R 7A , R 7B are each independently selected from hydrogen and Ci- 4 -alkyl, wherein any alkyl residue is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and Ci- 4 -alkoxy,
  • R 7A and R 7B together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring, optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, Ci- 4 -alkyl, fluoro- Ci- 4 -alkyl and Ci- 4 -alkoxy;
  • R 2 is H
  • R 3 and R 6 are each independently selected from H, C 4 alkyl, or cyclopropyl each of which C 4 alkyl, or cyclopropyl being optionally substituted with one or more substituents independently selected from fluoro and C 4 alkoxy;
  • W is an optionally substituted phenyl or pyridyl ring
  • B is selected from:
  • R 7 , R 8 , R 9 and R 10 are independently selected from H, d- 4 alkyl, or cyclopropyl, each of which C 4 alkyl, or cyclopropyl being optionally substituted with one or more substituents independently selected from fluoro and C 4 alkoxy; or
  • R 7 and R 8 together with the nitrogen atom to which they are attached form a 3-5 membered heterocyclic ring selected from aziridine, azetidine, and pyrrolidine each of which being optionally substituted with one or more substituents independently selected from fluoro and Ci- 4 alkoxy.
  • the compounds of the invention are antagonists of the PAR2 receptor. Therefore, in another broad aspect the invention provides the use of a compound of the invention in the treatment of, or in the preparation of a composition for treatment of, diseases or conditions responsive to the reduction of PAR2 mediated activity.
  • PAR2 mediated activity include inflammation such as intestinal inflammation and inflammatory skin diseases including psoriasis and itch, fibrosis, arthritis, pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma, and pancreatitis.
  • the compounds with which the invention is concerned may be used for the reduction of PAR2 mediated activity, ex vivo or in vivo.
  • the compounds of the invention may be used in the preparation of a composition for the treatment of conditions including inflammation such as intestinal inflammation and inflammatory skin diseases including psoriasis and itch, fibrosis, arthritis, pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma, and pancreatitis
  • inflammation such as intestinal inflammation and inflammatory skin diseases including psoriasis and itch, fibrosis, arthritis, pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma, and pancreatitis
  • the invention provides a method for the treatment of the foregoing disease types, which comprises administering to a subject suffering such disease an effective amount of a compound of the invention.
  • composition comprising a compound as claimed in any of the preceding claims, together with one or more pharmaceutically acceptable carriers and/or excipients.
  • the compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the compounds can be administered in a sublingual formulation, for example a buccal formulation.
  • the compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermal ⁇ , by inhalation, intranasally, or by infusion techniques.
  • the compounds may also be administered as suppositories.
  • the compounds may also be administered topically. Thus, the compounds of the invention are administered orally, or by inhalation, topically, or intranasally.
  • the compounds of the invention are administered orally and more preferably, the compounds of the invention are administered as a tablet or capsule. In the latter connection, administration of the compounds in a hard gelatine capsule form, or in one of the many sustained release formulations known in the art will often be preferred. In an alternative preferred embodiment the compounds of the invention are administered as a topical treatment.
  • the present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrroli
  • Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • the present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier in the form of a capsule or tablet.
  • the compounds of the invention are preferable administered topically.
  • the compounds may be formulated in any form suitable for topical administration including semi-solid, spray, medicated powders, solution, and medicated adhesive systems.
  • the compounds of the invention may be administered as external topicals that are spread, sprayed, or otherwise dispersed on to cutaneous tissues to cover the affected area. Topical drug delivery is especially effective in the fields of psoriasis, itch, and pain management.
  • Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the art. However, it is expected that a typical dose will be in the range from about 0.001 to 50 mg per kg of body weight.
  • C a - b -alkyl wherein a and b are integers denotes a straight or branched alkyl group having from a to b carbon atoms.
  • Ci- 4 -alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, / ' so-butyl, sec-butyl and ieri-butyl and
  • Ci- 6 -alkyl includes the foregoing and straight- and branched-chain pentyl and hexyl.
  • fluoro-C a - b -alkyl wherein a and b are integers denotes a straight or branched C a - b -alkyl group substituted by one or more fluorine atoms.
  • fluoro-Ci- 4 -alkyl includes fluoromethyl, trifluoromethyl, 2-fluoroethyl and 2,2,2-trifluoroethyl.
  • Ci_ 4 -alkoxy includes methoxy, ethoxy, n- propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec-butoxy and ieri-butoxy.
  • fluoro-C a - b -alkoxy wherein a and b are integers denotes a fluoro- C a _ b -alkyl group which is attached to the remainder of the molecule through an oxygen atom.
  • fluoro-Ci- 4 -alkoxy groups include trifluoromethoxy and
  • C a - b -alkoxy-C c - d -alky wherein a, b, c and d are integers denotes a straight or branched alkoxy group having from a to b carbon atoms connected to a straight or branched alkyl group having from c to d carbon atoms.
  • a, b, c and d are integers denotes a straight or branched alkoxy group having from a to b carbon atoms connected to a straight or branched alkyl group having from c to d carbon atoms.
  • 4 -alkoxy-Ci- 4 -alkyl includes methoxymethyl, methoxyethyl, ethoxyethyl, iso- propoxyethyl, n-butoxyethyl and ieri-butoxyethyl.
  • fluoro-C a - b -alkoxy-C c - d -alkyl wherein a, b, c and d are integers denotes a C a - b -alkoxy-C c - d -alkyl group substituted by one or more fluorine atoms.
  • fluoro-Ci- 4 -alkoxy-Ci- 4 -alkyl includes trifluoromethoxymethyl and trifluoromethoxyethyl.
  • C a - b -cycloalky wherein a and b are integers denotes a saturated monocyclic hydrocarbon ring having from a to b carbon atoms.
  • C3-5- cycloalkyl includes cyclopropyl, cyclobutyl and cyclopentyl.
  • C a - b -cycloalkyl-C c - d -alky wherein a, b, c and d are integers denotes a saturated monocyclic hydrocarbon ring having from a to b carbon atoms connected to a straight or branched alkyl group having from c to d carbon atoms.
  • C 3 -5-cycloalkyl-Ci- 4 -alkyl includes cyclopropylmethyl and cyclobutylmethyl.
  • the term “carbocyclic” refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl. Unless otherwise particularised, the term “heterocyclyl” or “heterocyclic ring” denotes a saturated, monocyclic ring having from 4 to 7 ring atoms with at least one heteroatom such as O, N, or S, and the remaining ring atoms are carbon.
  • heterocyclic rings examples include piperidinyl, tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dioxanyl, piperazinyl and homopiperazinyl.
  • Exemplary heterocyclic groups containing sulfur in oxidized form are 1 ,1 -dioxido-thiomorpholinyl and 1 ,1 -dioxido- isothiazolidinyl.
  • heterocyclyl-C a - b -alkyl wherein a and b are integers denotes a heterocyclic ring as defined above that is directly attached to a straight or branched C a -b-alkyl group via a carbon or nitrogen atom of said ring.
  • heterocyclyl-Ci- 4 -alkyl groups include piperidin-1 -ylmethyl, piperidin-4-ylmethyl and morpholin-4-ylmethyl.
  • heteroaryl denotes a monocyclic or fused bicyclic heteroaromatic ring system comprising 5 to 10 ring atoms in which one or more of the ring atoms are other than carbon, such as nitrogen, sulphur or oxygen. Only one ring need be aromatic and said heteroaryl moiety can be linked to the remainder of the molecule via a carbon or nitrogen atom in any ring.
  • heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, tetrazolyl, quinazolinyl, indolyl, indolinyl, isoindolyl, isoindolinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinolinyl, quinoxalinyl, oxadiazolyl, thiadiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 1 ,3- benzodioxolyl, 1 ,4-benzodioxinyl, benzothiazolyl, benzimidazolyl, azabenzimidazole, benzotriazolyl and chromanyl.
  • C a -b-aryl wherein a and b are integers denotes a monocyclic or fused bicyclic hydrocarbon ring system comprising a to b ring atoms and wherein at least one ring is an aromatic ring.
  • C 6 -io-aryl groups include phenyl, indenyl, 2,3-dihydroindenyl (indanyl), 1 -naphthyl, 2-naphthyl or 1 ,2,3,4-tetrahydronaphthyl.
  • C a - b -aryl-C c - d -alkyl wherein a, b, c and d are integers refers to a C a -b-aryl group that is directly linked to a straight or branched C c -d-alkyl group.
  • C 6 -io-aryl-Ci- 4 -alkyl groups include phenylmethyl (i.e., benzyl) and phenylethyl.
  • heteroaryl-C a -b-alkyl wherein a and b are integers denotes a heteroaryl ring as defined above that is directly linked to a straight or branched C a - b -alkyl group via a carbon or nitrogen atom of said ring.
  • heteroaryl-Ci- 4 -alkyl groups include 2-(pyridin-2-yl)-ethyl and 1 ,2,4- oxadiazol-5-ylmethyl.
  • substituted as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (CrC 6 )alkyl, (d-C 6 )alkoxy, hydroxy, hydroxy(CrC 6 )alkyl, mercapto, mercapto (CrC 6 )alkyl, (CrC 6 )alkylthio, phenyl, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, -COOH, -COOR A , -COR A , - S0 2 R A , -CONH 2 , -S0 2 NH 2 , -CONHR A , -S0 2 NHR A , -CONR A R B , -S0 2 NR A R B , -NH 2 , -NHR A ,
  • Compounds of the invention may exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and frans-forms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers may be prepared by the application of adaptation of known methods (e.g. asymmetric synthesis).
  • salt includes base addition, acid addition and ammonium salts.
  • compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine,
  • hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
  • organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p- toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like.
  • Those compounds (I) which have a basic nitrogen can also form quaternary ammonium salts with a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene-bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene-bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • Some compounds of the invention having a nitrogen atom in an aromatic ring, may form N-oxides, and the invention includes compounds of the invention in their N-oxide form.
  • the compounds of the invention in any compatible combination, and bearing in mind that the compounds preferably have a molecular weight of less than 600.
  • X is independently selected from a direct bond, -C(O)-, -(CHR 6 ) P - with p being 1 or 2, for example -(CH 2 ) P -, -(CHCH 3 ) P -, -(CHCH 2 CH 3 ) P -, -(CHCH 2 CH 2 CH 3 ) p , -(CHCH(CH 3 ) 2 ) p -, -(CHCH(CH 2 ) 3 ) P -, -(CHC(CH 3 ) 3 ) P -, -N(R 6 ) such as -NH, -N(CH 3 ), -N(CH 2 CH 3 ), -N(CH 2 CH 2 CH 3 ),-N(CH 2 C(CH 3 ) 2 ), or -NCH(CH 2 ) 3 or, in either orientation, -(CH 2 CHR 6 )-, for example -(CH 2 CHCH 3 )-;
  • Q is independently selected from a direct bond, -0-, -S-, -N(R 6 )-, -C(O)-, C(H)(OH)-, -(CHR 6 ) P - or, in either orientation, -(CH 2 CHR 6 )-, wherein, for example, each of -N(R 6 )-, -(CHR 6 ) P -, and -(CH 2 CHR 6 )- are defined for group X above.
  • X is independently selected from -C(O)-
  • Q is independently selected from -0-, -S-, -N(R 6 )-, -C(O)-, C(H)(OH)-, -(CHR 6 ) P - or, in either orientation, -(CH 2 CHR 6 )-.
  • the group U is either O (an oxygen atom), or S (a sulfur atom). In a preferred embodiment U is O.
  • R 3 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, C 4 alkyl such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, and sec-butyl, or cyclopropyl, and each of which C 4 alkyl or cyclopropyl being optionally substituted with one or more substituents independently selected from fluoro, and C 4 alkoxy such as methoxy, ethoxy, n-propoxy, / ' so-propoxy, n- butoxy, / ' so-butoxy, sec-butoxy and ieri-butoxy.
  • R 10 is hydrogen.
  • R 10 is C 4 alkyl
  • R 5 is a monocyclic aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 or 6 ring atoms such as phenyl, pyridyl, piperidine, pyrrole, imidazole, imidazoline, imidazolone , optionally fused to a second aromatic or non-aromatic monocyclic carbocyclic or heterocyclic ring such as phenyl or pyridyl to form a 5-5, 5-6, 6-5, or 6-6 bicyclic ring system, such as which monocyclic ring or bicyclic ring system is optionally substituted with one more substituents independently selected from halogen such as fluoro or chloro, hydroxy, cyano, nitro, CF 3 , Ci- 4 -alkyl such as methyl, or ethyl, Ci_ 4 -alkoxy and -NR 7A R 7B , wherein
  • R 7A , R 7B are each independently selected from hydrogen and Ci- 4 -alkyl, wherein any alkyl residue is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and Ci- 4 -alkoxy,
  • R 7A and R 7B together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring, optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, Ci- 4 -alkyl, fluoro- Ci- 4 -alkyl and Ci- 4 -alkoxy;
  • B is selected from:
  • R 7 , R 8 ,R 9 and R 10 are independently selected from H, or d- 4 alkyl such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, and sec-butyl, or cyclopropyl, and each of which C 4 alkyl or cyclopropyl being optionally substituted with one or more substituents independently selected from fluoro, chloro and bromo, and C 4 alkoxy such as methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec- butoxy and ieri-butoxy;
  • R 7 and R 8 together with the nitrogen atom to which they are attached form a 3-5 membered heterocyclic ring selected from aziridine, azetidine, and pyrrolidine each of which being optionally substituted with one or more substituents independently selected from fluoro, chloro and bromo, and C C 4 alkoxy such as methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec-butoxy and ieri- butoxy.
  • R 7 and R 8 are independently selected from H, C 4 alkyl, or cyclopropyl, each of which C 4 alkyl, or cyclopropyl being optionally substituted with one or more substituents independently selected from fluoro, and C C 4 alkoxy.
  • the bond marked * connects to the carbon of the carbonyl group.
  • the ring comprising Z and Y is optionally substituted with one more substituents independently selected from fluoro, Ci- 4 -alkyl such as methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, and sec-butyl, Ci_ 4 -alkoxy such as methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec-butoxy and ieri-butoxy, fluoro-Ci- 4 -alkyl such as fluoromethyl, trifluoromethyl, 2-fluoroethyl and 2,2,2- trifluoroethyl, and fluoro-Ci- 4 -alkoxy such as trifluoromethoxy and 2,2,2- trifluoroethoxy.
  • radical -(W) v (CH 2 ) t B is selected from:
  • the bond marked * is connected to the CH 2 of the rest of the molecule, and R 7 , R 8 ,R 9 and R 10 are as previously defined.
  • the phenyl ring is substituted with one or more fluoro substituents.
  • W is an optionally substituted phenyl or pyridyl ring.
  • W is an optionally substituted phenyl ring.
  • the group B and the CH 2 of the rest of the molecule are connected to the W ring in a para arrangement.
  • R 4 is selected from:
  • the phenyl ring is substituted with one or more fluoro substituents, preferably one or two or three fluoro substituents.
  • R 3 is H.
  • R 6 is H or methyl
  • R 9 is H or methyl.
  • R 5 is selected from:
  • bond marked * connects R 5 to the rest of the molecule, each of which being optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, CF 3 , d_ 4 -alkyl such as methyl, ethyl, d_ 4 -alkoxy such as methoxy, ethoxy, and -NR 7A R 7B , wherein R 7A , R 7B are each independently selected from hydrogen and Ci-C 4 -alkyl, wherein any alkyl residue is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and Ci- 4 -alkoxy,
  • R 7A and R 7B together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring, optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, Ci-C 4 -alkyl, fluoro- Ci-C 4 -alkyl and Ci-C 4 -alkoxy.
  • R 1* is either R 1 or a functional group that can be readily converted in to R 1 .
  • the compounds of Formula (I) above may be prepared by the condensation of the appropriate primary amine, NH(R 2 )CH 2 R 1* with (a) activated ureas, (b) amines or (c) carboxylic acids using standard procedures. All of these alternatives are exemplified in the experimental section below.
  • High-resolution mass spectra were obtained on an Agilent MSD- TOF connected to an Agilent 1 100 HPLC system. During the analyses the calibration was checked by two masses and automatically corrected when needed. Spectra are acquired in positive electrospray mode. The acquired mass range was m/z 100-1 100. Profile detection of the mass peaks was used. Analytical HPLC was performed on either an Agilent 1 100 system using a Phenomenex Synergi, RP- Hydro, 150 x 4.6 mm, 4 ⁇ m column with a flow rate of 1 .5 ml_ per min at 30°C (200-
  • Reverse Phase HPLC was performed on a Gilson system (Gilson 322 pump with Gilson 321 equilibration pump and Gilson 215 autosampler) equipped with Phenomenex Synergi Hydro RP 150 x 10 mm, or YMC ODS-A 100/150 x 20 mm columns, or on an XTerra Prep MS C18 5 urn 19 x 50 mm system. Microwave irradiations were carried out using a Biotage microwave. Reactions were performed at room temperature unless otherwise stated. The compounds were automatically named using ACD 6.0. All compounds were dried in a vacuum oven overnight. Where yields are not included, the intermediates were used crude. Reactions were monitored by TLC, LCMS or HPLC.
  • CDI (441 mg, 2.72 mmol) was dissolved in DCM (25 mL) and cooled to 0°C.
  • CDI (613 mg, 3.78 mmol) was dissolved in DCM (30 mL) and cooled to 0°C.
  • Example 49 (100 mg, 0.29 mmol) and Cs 2 C0 3 (90.0 mg, 0.29 mmol) were dissolved in DMF (2 mL), iodomethane (18.0 ⁇ , 0.29 mmol) was added and the mixture stirred for 3 h. The reaction mixture was diluted with MeOH and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (21 .1 mg, 20%) as a white solid. HRMS calculated for C22H26N40: 362.210661 , found 362.212241 . HPLC: Rf 5.24 min, 99.3%.
  • Examples 56-60 were prepared similarly to Example 55, using the appropriate commercially available cyclic amine derivative instead of 4-(4- fluorophenoxy)piperidine; see Table 5 below. Table 5: Urea formation from 1H-13-benzodiazol-6-ylmethanamine.
  • Examples 64-68 were prepared similarly to Example 63; see Table 6 below.
  • the PAR2 receptor couples through the Gq signaling pathway and results in activation of calcium mobilization.
  • the functional activity of test compounds was routinely tested by measuring the ability of compounds to antagonize PAR2 (trypsin challenge) activity in a dose dependent manner, in 1321 N1 cells transfected with the human PAR2 receptor, using a calcium flux Fluorescent Imaging Plate Reader FLIPR assay. To provide confirmation of functional inhibition, compounds were also examined at the native PAR2 receptor expressed in the A549 cell line.
  • test compounds were dissolved in DMSO to a concentration of 20 mM and stored in matrix screenmate racks.
  • the required amount of compound was transferred to 96-well compound plates on the day of assay and diluted in assay buffer to the required final concentration; dose-response measurements were assayed by making 1 :3.16 serial dilutions to produce 10 point curves.
  • the compounds were then transferred to 384-well assay plates ready for use. Top concentrations were adjusted depending on the potency of the compounds with a typical concentration range of 200 ⁇ to 6.3 nM being used.
  • the assay buffer used was HBSS buffer supplemented with 20 mM HEPES and 0.1 % BSA (protease free), pH7.4.
  • the loading/wash buffers were the same as the assay buffer.
  • the cells were lifted using Ca 2+ and Mg 2+ free PBS/0.02% (w/v) EDTA, spun at 1000 rpm for 3 min and re-suspended in medium at 2 x 10 5 cells/mL, transferred (50 ⁇ /well) to 384-well black/clear Costar plates (Costar #3712) and incubated at 37°C in a 5% C0 2 /95% air humidified incubator for 4 h.
  • the cells were washed with assay buffer at 37 °C using the Biotek ELx 405, washing 3 times, leaving 20 ⁇ buffer in the well.
  • a combined agonist/antagonist protocol was used to measure changes in intracellular calcium concentration.
  • Compound (antagonist) was added to the cell plate using a Fluorometric Imaging Plate Reader (FLIPR) (Molecular Devices, Sunnyvale, CA, USA). Basal fluorescence was recorded every second for 10 seconds prior to compound addition (10 ⁇ ) and fluorescence recorded every second for 1 min then every 6 seconds for a further 1 min. Trypsin (EC 50 concentration) was then added using the FLIPR and fluorescense recorded as described above. Curve-fitting and parameter estimation were carried out using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA).
  • the kit quantifies trypsin activity by measuring the cleaved product of FTC-casein. To measure enzyme inhibition activity, compounds were pre-incubated with trypsin before the addition of substrate. Compound IC50 was determined as percentage inhibition of trypsin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
EP12701772.1A 2011-01-28 2012-01-27 Antagonistes du récepteur 2 activé par des protéases (par2) Withdrawn EP2668157A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1101517.9A GB201101517D0 (en) 2011-01-28 2011-01-28 Receptor antagonists
PCT/GB2012/050177 WO2012101453A1 (fr) 2011-01-28 2012-01-27 Antagonistes du récepteur 2 activé par des protéases (par2)

Publications (1)

Publication Number Publication Date
EP2668157A1 true EP2668157A1 (fr) 2013-12-04

Family

ID=43824760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12701772.1A Withdrawn EP2668157A1 (fr) 2011-01-28 2012-01-27 Antagonistes du récepteur 2 activé par des protéases (par2)

Country Status (11)

Country Link
US (1) US20130324556A1 (fr)
EP (1) EP2668157A1 (fr)
JP (1) JP2014514246A (fr)
CN (1) CN103339108A (fr)
AU (1) AU2012210348A1 (fr)
BR (1) BR112013018290A2 (fr)
CA (1) CA2824536A1 (fr)
EA (1) EA201370149A1 (fr)
GB (1) GB201101517D0 (fr)
SG (1) SG191870A1 (fr)
WO (1) WO2012101453A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030024B2 (en) 2013-09-25 2018-07-24 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI732031B (zh) * 2016-08-31 2021-07-01 日商衛材R&D企管股份有限公司 吡唑并[1, 5-a]嘧啶化合物
SG11202005926XA (en) 2018-02-26 2020-07-29 Eisai R&D Man Co Ltd SALT OF PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND AND CRYSTALS THEREOF
RU2704967C1 (ru) * 2018-06-19 2019-11-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный педагогический университет им. К.Д. Ушинского (ЯГПУ им. К.Д. Ушинского) Карбоксамидные производные изоксазолина, способ их получения и применения для лечения воспалительных заболеваний
WO2020201572A1 (fr) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Inhibiteurs du récepteur 2 activé par une protéase pour le traitement d'une neuropathie sensorielle induite par une intoxication neurotoxique marine
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
EP4313302A1 (fr) 2021-03-23 2024-02-07 Bioage Labs, Inc. Inhibiteurs de l'inflammasome nlrp3
US11787805B2 (en) 2022-01-28 2023-10-17 BioAge Labs, Inc. N-oxide inhibitors of NLRP3 inflammasome
WO2023233033A1 (fr) 2022-06-03 2023-12-07 Domain Therapeutics Nouveaux inhibiteurs de par-2
WO2025172573A1 (fr) 2024-02-16 2025-08-21 Domain Therapeutics Combinaisons d'inhibiteurs de par2 et d'inhibiteurs de points de contrôle immunitaires pour le traitement du cancer
WO2025191185A1 (fr) 2024-03-15 2025-09-18 Domain Therapeutics Composés à base d'azine utilisés en tant qu'inhibiteurs de par-2 et leurs utilisations thérapeutiques
WO2025224085A1 (fr) * 2024-04-23 2025-10-30 Universitat De Barcelona Composés capables d'agir sur le s1r ainsi que sur la seh et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087038B1 (es) * 1994-11-07 1997-03-16 Uriach & Cia Sa J Nuevas piperidinas con actividad antagonista del paf.
DE19715341C1 (de) * 1997-04-12 1998-10-15 Vossloh Schwabe Gmbh Elektronisches Vorschaltgerät mit automatischem Wiederanlauf
TWI283665B (en) * 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
WO2005047253A1 (fr) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Agonistes du récepteur de la mélanocortine
CA2576971A1 (fr) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012101453A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030024B2 (en) 2013-09-25 2018-07-24 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Also Published As

Publication number Publication date
WO2012101453A1 (fr) 2012-08-02
CA2824536A1 (fr) 2012-08-02
AU2012210348A1 (en) 2013-07-11
BR112013018290A2 (pt) 2016-11-16
GB201101517D0 (en) 2011-03-16
CN103339108A (zh) 2013-10-02
US20130324556A1 (en) 2013-12-05
JP2014514246A (ja) 2014-06-19
EA201370149A1 (ru) 2014-01-30
SG191870A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
EP2668157A1 (fr) Antagonistes du récepteur 2 activé par des protéases (par2)
KR100979577B1 (ko) 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체
EP3606519B1 (fr) Composés inhibiteurs d'ask1 et utilisations associées
WO2014020351A1 (fr) Antagonistes de récepteur
US20080103141A1 (en) New compounds
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
TW200808788A (en) Azolecarboxamide derivative
WO2006113140A2 (fr) Nouveaux composes s'utilisant dans l'antagonisme du recepteur de bradykinine b1
CA2962917C (fr) Nouveaux composes de pyridopyrimidinone pour moduler l'activite catalytique des histone lysine demethylases (kdm)
CN114728170B (zh) 对核受体具有活性的化合物
AU2007264791A1 (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
JP6599908B2 (ja) ニューロテンシン受容体１の小分子アゴニスト
JP2010523530A (ja) タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン
CN1387526A (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
US20240374738A1 (en) Bifunctional compound capable of degrading receptor tyrosine kinase and application thereof
CN107922400A (zh) 毒蕈碱m1受体正变构调节剂
JP2010517966A (ja) 摂食障害の処置のための１−オキサ−３−アザスピロ（４．５）デカン−２−オンおよび１−オキサ−３，８−ジアザスピロ（４．５）デカン−２−オン誘導体
WO2006071775A2 (fr) Composes utiles pour l'antagonisme du recepteur b1 de la bradykinine
JP2008538357A (ja) 薬学的に活性なジアゼパン
JPWO2017099049A1 (ja) Ｎｋ１受容体拮抗剤
US20170007610A1 (en) Novel heterobicyclic compounds as kappa opioid agonists
US20240051946A1 (en) Targeted protein degradation of parp14 for use in therapy
WO2024167423A1 (fr) Composés de dégradation de gspt1
CN120530120A (zh) 可用作mk2激酶的降解剂的化合物和组合物
HK1189227A (en) Protease activated receptor 2 (par2) antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150801